Barclays PLC Has $189,000 Stock Position in PepGen Inc. (NASDAQ:PEPG)

Barclays PLC lifted its position in PepGen Inc. (NASDAQ:PEPG) by 318.7% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 21,971 shares of the company’s stock after buying an additional 16,723 shares during the period. Barclays PLC’s holdings in PepGen were worth $189,000 as of its most recent SEC filing.

Several other hedge funds have also added to or reduced their stakes in PEPG. Suvretta Capital Management LLC raised its holdings in shares of PepGen by 9.2% during the third quarter. Suvretta Capital Management LLC now owns 1,660,932 shares of the company’s stock worth $14,201,000 after acquiring an additional 140,000 shares during the period. Sofinnova Investments Inc. raised its stake in shares of PepGen by 11.4% in the 2nd quarter. Sofinnova Investments Inc. now owns 561,128 shares of the company’s stock valued at $8,956,000 after purchasing an additional 57,504 shares during the period. Janus Henderson Group PLC raised its stake in shares of PepGen by 331.2% in the 3rd quarter. Janus Henderson Group PLC now owns 2,336,516 shares of the company’s stock valued at $20,012,000 after purchasing an additional 1,794,641 shares during the period. American Century Companies Inc. lifted its holdings in shares of PepGen by 19.9% in the second quarter. American Century Companies Inc. now owns 20,028 shares of the company’s stock valued at $320,000 after purchasing an additional 3,326 shares in the last quarter. Finally, Renaissance Technologies LLC acquired a new position in shares of PepGen during the second quarter worth about $192,000. Institutional investors and hedge funds own 58.01% of the company’s stock.

PepGen Stock Down 3.9 %

PEPG stock opened at $3.68 on Tuesday. The company has a market cap of $119.95 million, a price-to-earnings ratio of -1.23 and a beta of 1.66. PepGen Inc. has a twelve month low of $2.90 and a twelve month high of $19.30. The business has a 50 day moving average price of $4.93 and a two-hundred day moving average price of $9.21.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on PEPG shares. HC Wainwright restated a “buy” rating and issued a $26.00 target price on shares of PepGen in a research note on Friday, November 8th. Bank of America lowered shares of PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 price objective on the stock. in a research report on Monday, December 16th. Finally, Wedbush decreased their target price on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating for the company in a research report on Friday, November 8th.

PepGen Profile

PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.